BioLineRx Ltd. - American Depositary Shares (BLRX)
3.6300
+0.1500 (4.31%)
Biolinerx Ltd is a biopharmaceutical company that focuses on the development of innovative therapies for cancer and other diseases
The company is engaged in the research and clinical development of a diverse pipeline of drug candidates, aiming to address unmet medical needs through cutting-edge technologies and unique approaches. Biolinerx collaborates with various academic institutions and industry partners to enhance its product offerings and accelerate the development of its therapeutic solutions, striving to improve patient outcomes and quality of life in the medical field.
San Diego, CA -- (SBWIRE) -- 04/24/2023 -- An investigation was announced for current long-term investors in shares of BioLineRx Ltd. (NASDAQBLRX) concerning potential breaches of fiduciary duties by certain directors of BioLineRx Ltd.
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioLineRx Ltd. (NASDAQBLRX) between February 23, 2021 and September 19, 2022, both dates inclusive (the “Class Period”), of the important March 6, 2023 lead plaintiff deadline.
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against BioLineRx Ltd. (“BioLineRx” or the “Company”) (NASDAQBLRX) in the United States District Court for the District of New Jersey on behalf of all persons and entities who purchased or otherwise acquired BioLineRx securities between February 23, 2021 and September 19, 2022, both dates inclusive (the “Class Period”). Investors have until March 6, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
The Law Offices of Frank R. Cruz reminds investors of the upcoming March 6, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired BioLineRx Ltd. (“BioLine” or the “Company”) (NASDAQBLRX) American Depositary Shares (“ADSs”) between February 23, 2021 and September 19, 2022, inclusive (the “Class Period”).
San Diego, CA -- (SBWIRE) -- 02/21/2023 -- A deadline is coming up on March 6, 2023 in the lawsuit filed for certain investors of BioLineRx Ltd. (NASDAQBLRX).
NEW YORK, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of BioLineRx Ltd. (NASDAQBLRX), Enovix Corporation NASDAQ: ENVXNASDAQENVX)(NYSE: LUVNYSELUV, and Y-mAbs Therapeutics, Inc. (NASDAQ: YMABNASDAQ). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
NEW YORK, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of BioLineRx Ltd. (NASDAQBLRX), Enovix Corporation NASDAQ: ENVXNASDAQENVX)(NYSE: LUVNYSELUV, and Y-mAbs Therapeutics, Inc. (NASDAQ: YMABNASDAQ). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
NEW YORK, Jan. 29, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of BioLineRx Ltd. (NASDAQBLRX), Enovix Corporation NASDAQ: ENVXNASDAQENVX)(NYSE: LUVNYSELUV, and Y-mAbs Therapeutics, Inc. (NASDAQ: YMABNASDAQ). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
